Ad-hoc | 29 April 2020 12:45
|
Aladdin Healthcare Technologies SE / Key word(s): Joint Venture
Aladdin Healthcare Technologies sets up Joint Venture with Chinese partner network and wins new customer – first sales revenues of EUR 120,000
The goal of the joint venture (JV), in which Aladdin Healthcare holds a 51% stake, is the further global development and marketing of an AI-based drug discovery tool. The tool supports basic clinical research for the development of new drugs for age-related diseases such as Alzheimer’s, cardiovascular diseases, pulmonary diseases, diabetes and osteoporosis. At the same time, Aladdin has gained a new customer. The order volume for the use of the AI platform and for consultancy services is EUR 120,000.
Contact Press
29-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|
| Language: | English |
| Company: | Aladdin Healthcare Technologies SE |
| Unter den Linden 10 | |
| 10117 Berlin | |
| Germany | |
| Phone: | 030 700140449 |
| E-mail: | info@aladdinid.com |
| Internet: | www.aladdinid.com |
| ISIN: | DE000A12ULL2 |
| WKN: | A12ULL |
| Listed: | Regulated Market in Dusseldorf |
| EQS News ID: | 1032909 |
| End of Announcement | DGAP News Service |